Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 22, 2023 - Issue 1
Submit an article Journal homepage
2,318
Views
1
CrossRef citations to date
0
Altmetric
Original Research

Safety profile of lasmiditan in patients with migraine in an Asian population

Koichi Hirataa Headache Center, Dokkyo Medical University, Mibu, JapanView further author information
,
Yasuhiko Matsumorib Sendai Headache and Neurology Clinic, Sendai, JapanView further author information
,
Yuka Tanjic Japan Drug Development and Medical Affairs, Eli Lilly Japan K.K., Kobe, JapanView further author information
,
Rashna Khannad Global Patient Safety, Eli Lilly and Company Limited, Bracknell, UKView further author information
,
Akichika Ozekic Japan Drug Development and Medical Affairs, Eli Lilly Japan K.K., Kobe, JapanView further author information
&
Mika Komoric Japan Drug Development and Medical Affairs, Eli Lilly Japan K.K., Kobe, JapanCorrespondence[email protected]
View further author information
Pages 91-101 | Received 28 Mar 2022, Accepted 06 Jun 2022, Published online: 12 Jul 2022

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

Order Reprints Request Permissions

For more information please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.